ketanserin has been researched along with Cardiovascular Stroke in 14 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a 7-center Scandinavian double-blind placebo-controlled study of 179 patients with intermittent claudication, the effect of the serotonin antagonist ketanserin was evaluated on walking distance, brachial and ankle blood pressure, and symptoms." | 9.06 | Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. ( Akesson, H; Brunes, L; Einarsson, E; Gjöres, JE; Hallböök, T; Kroese, A; Lundvall, J; Ohlin, P; Stranden, E; Thulesius, O, 1987) |
| "In a 7-center Scandinavian double-blind placebo-controlled study of 179 patients with intermittent claudication, the effect of the serotonin antagonist ketanserin was evaluated on walking distance, brachial and ankle blood pressure, and symptoms." | 5.06 | Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. ( Akesson, H; Brunes, L; Einarsson, E; Gjöres, JE; Hallböök, T; Kroese, A; Lundvall, J; Ohlin, P; Stranden, E; Thulesius, O, 1987) |
| "To determine whether ketanserin, an antagonist at the serotonin receptor, prevents important vascular events such as death, myocardial infarction, major stroke, and amputation of a leg in patients with claudication." | 5.06 | Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. ( , 1989) |
| "Increased residual platelet reactivity remains a burden for coronary artery disease (CAD) patients who received a coronary stent and do not respond sufficiently to treatment with acetylsalicylic acid and clopidogrel." | 3.78 | Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. ( Ahrens, I; Bode, C; Brandt, C; Duerschmied, D; Mauler, M; Moser, M; Weidner, S, 2012) |
| "Rats with congestive heart failure (CHF) develop ventricular inotropic responsiveness to serotonin (5-HT), mediated through 5-HT(2A) and 5-HT(4) receptors." | 1.34 | Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes. ( Birkeland, JA; Enger, U; Levy, FO; Lunde, PK; Qvigstad, E; Sejersted, OM; Sjaastad, I; Swift, F; Tovsrud, N, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, JG | 2 |
| Zhang, EH | 1 |
| Liu, AJ | 2 |
| Liu, JG | 1 |
| Cai, GJ | 1 |
| Su, DF | 3 |
| Song, SW | 1 |
| Shu, H | 2 |
| Fan, SJ | 1 |
| Liu, C | 1 |
| Guo, W | 1 |
| Guo, JM | 1 |
| Miao, CY | 2 |
| Duerschmied, D | 1 |
| Ahrens, I | 1 |
| Mauler, M | 1 |
| Brandt, C | 1 |
| Weidner, S | 1 |
| Bode, C | 1 |
| Moser, M | 1 |
| Fu, YJ | 1 |
| Wang, MW | 1 |
| Birkeland, JA | 1 |
| Swift, F | 1 |
| Tovsrud, N | 1 |
| Enger, U | 1 |
| Lunde, PK | 1 |
| Qvigstad, E | 1 |
| Levy, FO | 1 |
| Sejersted, OM | 1 |
| Sjaastad, I | 1 |
| Hartford, CG | 1 |
| Rogers, GG | 1 |
| Marcos, EF | 1 |
| Rosendorff, C | 1 |
| Hirata, Y | 1 |
| Umemura, K | 1 |
| Uematsu, T | 1 |
| Nakashima, M | 1 |
| Sellke, FW | 1 |
| Wang, SY | 1 |
| Friedman, M | 1 |
| Harada, K | 1 |
| Edelman, ER | 1 |
| Grossman, W | 1 |
| Simons, M | 1 |
| Brune, S | 1 |
| Tebbe, U | 1 |
| Schmidt, T | 1 |
| Benn, HP | 1 |
| Seiler, KU | 1 |
| Kreuzer, H | 1 |
| De Cree, J | 2 |
| Leempoels, J | 2 |
| Demoen, B | 2 |
| Verhaegen, H | 2 |
| Thulesius, O | 1 |
| Lundvall, J | 1 |
| Kroese, A | 1 |
| Stranden, E | 1 |
| Hallböök, T | 1 |
| Brunes, L | 1 |
| Gjöres, JE | 1 |
| Akesson, H | 1 |
| Einarsson, E | 1 |
| Ohlin, P | 1 |
| Roels, V | 1 |
| David, JL | 1 |
4 trials available for ketanserin and Cardiovascular Stroke
| Article | Year |
|---|---|
Ketanserin and red blood cell sodium content in hypertension.
Topics: Adult; Aged; Erythrocyte Deformability; Erythrocytes; Humans; Hypertension; Ketanserin; Middle Aged; | 1985 |
Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Blood Pressure; Cardiovascular System; Clinical Tr | 1987 |
Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.
Topics: Adult; Amputation, Surgical; Arteriosclerosis; Cardiovascular Diseases; Cause of Death; Cerebrovascu | 1989 |
The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
Topics: Aged; Arterial Occlusive Diseases; beta-Thromboglobulin; Cardiovascular Diseases; Double-Blind Metho | 1985 |
10 other studies available for ketanserin and Cardiovascular Stroke
| Article | Year |
|---|---|
Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function.
Topics: Acetylcholine; Animals; Baroreflex; Enzyme-Linked Immunosorbent Assay; Heart; Ketanserin; Myocardial | 2013 |
Baroreflex deficiency hampers angiogenesis after myocardial infarction via acetylcholine-α7-nicotinic ACh receptor in rats.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Angiogenesis Inducing Agents; Animals; Baror | 2013 |
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techn | 2012 |
Restoration of baroreflex function by ketanserin is not blood pressure dependent in conscious freely moving rats.
Topics: Animals; Antihypertensive Agents; Baroreflex; Blood Pressure; Female; Ketanserin; Male; Myocardial I | 2004 |
Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Calcium Channels, L-Type; Calcium Signaling; C | 2007 |
Influence of ketanserin on regional myocardial blood flow after myocardial infarction in baboons.
Topics: Animals; Chromatography, High Pressure Liquid; Coronary Circulation; Female; Hemodynamics; Ketanseri | 1993 |
An experimental myocardial infarction model in the rat and its properties.
Topics: Animals; Biphenyl Compounds; Clopidogrel; Coronary Vessels; Disease Models, Animal; Electrocardiogra | 1995 |
Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Adenosine Diphosp | 1994 |
Prevention of an early re-occlusion after thrombolytic therapy of acute myocardial infarction by ketanserin.
Topics: Adult; Aged; Female; Humans; Ketanserin; Male; Middle Aged; Myocardial Infarction; Recombinant Prote | 1990 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |